← Back to home
2/10
Mostly Real
BS Scale Score
Solid evidence from human clinical trials
"AOD-9604 burns fat without diet or exercise"
1-3
Mostly Real
4-6
Overhyped
7-10
Mostly BS
It failed its Phase 3 obesity trial. The company dissolved. The bro science did not.
AOD-9604 is a modified fragment of human growth hormone that showed fat-burning effects in obese mice. Metabolic Pharmaceuticals ran it through Phase 2 and Phase 3 human trials for obesity — and it didn't beat placebo. The program was discontinued. The compound is currently marketed as a "lipolytic peptide" on gray-market research chemical sites, citing the same rodent data that preceded the failed human trials. Injecting something that couldn't pass Phase 3 is a remarkable act of faith.
Ready to talk to a real doctor?

We've vetted clinicians who practice evidence-based peptide therapy and won't sell you a TikTok protocol.

Find a Vetted Clinician →

Score Your Own Claim

Think you have a peptide claim that can't be debunked? Let's find out.

Try the Claim Scorer